查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138406

2022-2029 年註意力缺陷多动障碍的全球市场

Global Attention-Deficit Hyperactivity Disorder Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

增加获得用于治疗精神疾病的健康保险的机会，并增加多动症的患病率

由于获得心理健康治疗的健康保险的机会增加，预计市场将增长。

健康保险是指针对未来手术或医疗费用的保险。这是一份合同，个人或一群人通过该合同为其健康保险支付称为预购保费的费用。根据保险类型的不同，被保险人自掏腰包支付医疗费用并由保险公司报销，或者保险公司直接向服务提供商付款。来自全国心理健康调查 (NMHS) 的数据显示，在低收入、就业有限和教育水平低的家庭中，精神障碍明显更高，因此更容易患上精神障碍。同时，这些相同的因素限制了获得和使用精神卫生服务。

预计 ADHD 患病率的上升将推动市场增长。

多动症的患病率在全球范围内差异很大，从低至 1% 到接近 20% 不等，具体取决于所使用的诊断标准和评估工具。据估计，多动症的全球患病率为 5.3%，是儿童中最常见的精神障碍。 ADHD（注意力缺陷多动障碍）占因残疾而损失的总年数的 0.06%，占所有死亡人数的 0.02%。多动症造成的大部分负担发生在儿童时期。在早期干预和治疗方面，需要提请决策者註意多动症造成的负担的严重程度。

注意缺陷多动障碍 (ADHD) 是儿童和青春期最常见的神经发育障碍，影响所有学龄儿童和青少年的 2.2-17.8%。儿童多动症与广泛的发育障碍有关，包括对学习或执行功能的控制有限，以及社交技能的全面损害。

与 ADHD 药物相关的副作用预计会阻碍市场增长。

虽然兴奋剂在减轻 ADHD 症状方面非常有效，但一些儿童会出现令人不快甚至有害的副作用。如果副作用成为问题，医生可能会尝试改变您孩子服用的药物量、给药方式或类型。目标是了解什么是有效的，同时尽量减少副作用。我很难入睡，因为睡前太刺激了，我经常在电脑上做一些事情来让自己平静下来。如果药物失效，多动症可能会让他们保持清醒。

另一种 ADHD 药物阿托西汀 (Straterra) 虽然不是兴奋剂，但与成人心律不齐有关。 FDA 建议有这些问题历史的人远离他人。多动症药物可能与一些精神问题有关，但这种情况很少见。例如，有些人报告了攻击性和敌意等行为问题。相比之下，其他人已经出现了双相情感障碍的症状。 FDA 还警告说，兴奋剂 ADHD 药物导致幻觉、抑郁和偏执狂等精神病症状的风险很小。

COVID-19 影响分析

在 COVID-19 大流行期间，多项协议影响了医疗实践。与这种流行病相关的注意力缺陷多动障碍 (ADHD) 问题的诊断和监测程序受到了影响。由于存在 COVID-19 的风险，人们害怕寻求治疗 ADHD 或购买药物，这对注意力缺陷多动障碍 (ADHD) 市场产生了影响。

行业分析

注意力缺陷多动障碍市场根据各种行业因素（包括未满足的需求、定价分析、供应链分析和监管分析）对市场进行了深入分析。

全球注意力缺陷多动障碍市场报告提供大约 45 多个市场数据表、40 多个数字和 180 页结构。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按药物类型划分的市场细分
  • 按年龄组划分的市场细分
  • 按分销渠道划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 增加获得用于治疗精神疾病的医疗保险的机会
      • 注意力缺陷多动障碍 (ADHD) 市场因注意力缺陷多动障碍 (ADHD) 发病率上升而扩大
    • 限制因素
      • 与 ADHD 药物相关的副作用正在阻碍注意力缺陷多动障碍 (ADHD) 市场。
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 流行病学分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按药物类型

  • 兴奋剂
  • 无刺激性

第 8 章年龄组

  • 童年和青春期
  • 成人

第 9 章分销渠道

  • 零售药房
  • 电子商务

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表
  • 拥有颠覆性技术的公司名单
  • 创业公司名单

第 12 章公司简介

  • Supernus Pharmaceuticals, Inc.
    • 公司概况
    • 产品组合和内容
    • 主要亮点
    • 财务摘要
  • Pfizer Inc
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Mallinckrodt Pharmaceuticals
  • Johnson & Johnson
  • Hisamitsu Pharmaceutical Co., Inc.,
  • Chongqing Fujin Biology Medical Company
  • Wanbang Medical Company LIST NOT EXHAUSTIVE

第13章 DataM

简介目录
Product Code: DMPH3819

Market Oveview

Attention-Deficit Hyperactivity Disorder Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.0% during the forecast period (2022-2029).

Attention-deficit hyperactivity disorder (ADHD) is a disorder that is marked by an ongoing pattern of hyperactivity-impulsivity and inattention that interferes with functioning or development.

Market Dynamics

The increasing access to health insurance for mental health treatment and rising incidence of ADHD.

The increasing access to health insurance for mental health treatment is expected to drive market growth.

Health insurance is defined as insurance for future surgical or medical expenditures. It is a contract where an individual or group of people by paying a fee called the premium purchase in advance for their health coverage. Based on the type of plan, usually, the insured person is either required to pay for the health expenses from their pocket, which the insurance company then reimburses or the expenses are directly paid by the insurance provider who pays it to the service provider. Data from the National Mental Health Survey (NMHS) reveal that mental disorders are significantly higher in households with lesser income, limited employment, and low levels of education, thus making it evident that they have a greater vulnerability to mental disorders. At the same time, these same factors also limit their access to and utilization of mental health services.

The rising incidence of ADHD is expected to drive market growth.

The prevalence of ADHD is highly variable worldwide, ranging from as low as 1% to nearly 20%, depending on the diagnostic criteria and the assessment tools used. With an estimated worldwide-pooled prevalence of 5.3%, ADHD is the most prevalent mental disorder in children. ADHD (attention-deficit hyperactive disorder) is responsible for 0.06% of total years lost to disability and 0.02% of total DALYs. The majority of the burden due to ADHD occurs in childhood. The magnitude of the burden attributable to ADHD needs the attention of policymakers in terms of early intervention and treatment.

Attention-deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in childhood and adolescence, affecting 2.2 to 17.8% of all school-aged children and adolescents. ADHD in children has been associated with a wide range of developmental deficits, including limitations of learning or control of executive functions and global impairments of social skills.

Side effects associated with ADHD drugs are expected to hamper market growth.

In reducing symptoms of ADHD, stimulant medications can be very effective, but some kids experience uncomfortable or harmful side effects. When side effects become a problem, doctors try to change the dosage, the release formula, or the type of medication a child takes. The goal is to understand what will benefit them with the least side effects. Trouble sleep may also be caused by kids being too stimulated at bedtime, often by doing something on the computer to calm themselves. Their ADHD may keep them awake if the medication has worn off.

Another ADHD medication, atomoxetine (Strattera), isn't a stimulant but has been linked to adults and irregular heartbeats. The FDA suggests people with a history of these problems stay away from others. ADHD drugs may be connected to some mental health issues, but it's rare. For instance, some people have reported behavior problems like aggression and hostility. In contrast, others developed symptoms of bipolar disorder. The FDA also warned that there's a slight risk that stimulant ADHD drugs could lead to symptoms of psychosis-like hearing things or mood swings and paranoia.

COVID-19 Impact Analysis

Due to several protocols, medical practices have been affected during the COVID-19 pandemic. The procedures for diagnosis and monitoring attention deficit hyperactivity disorder (ADHD) problems involved in this pandemic have been affected. As people are scared to undergo therapies for ADHD or even buy the medication due to the risk of COVID-19, there has been an impact on the attention deficit hyperactivity disorder (ADHD) market.

Industry Analysis

The attention-deficit hyperactivity disorder market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Stimulants segment is expected to hold the largest market share in the attention-deficit hyperactivity disorder Market

Stimulants effectively manage ADHD symptoms such as short attention span, impulsive behavior, and hyperactivity. Many stimulants are available: short-acting (immediate-release), intermediate-acting, and long-acting. The commonly used treatment for Attention-Deficit Disorder/ Hyperactivity Disorder is stimulant therapy. Stimulants effectively manage ADHD symptoms such as impulsive behavior, short attention span, and hyperactivity. They may be used alone or in combination with behavior therapy. These drugs improve ADHD symptoms in about 70% of adults and 70% to 80% of children shortly after starting treatment. Improvements include reduced interrupting, fidgeting, and other hyperactive symptoms, home relationships, and improved task completion. Improvements in behavior and attention span usually continue as long as the medication is taken. However, social adjustment and school performance benefits have not yet been shown to endure over the long term.

Currently, the most commonly prescribed medications for ADHD are stimulant drugs (psychostimulants). Stimulants appear to boost and balance levels of brain chemicals called neurotransmitters. These medications help improve the signs and symptoms of inattention and hyperactivity, sometimes in a short period. Amphetamines include dextroamphetamine (Dexedrine),dextroamphetamine-amphetamine, and lisdexamfetamine (Vyvanse). Stimulant drugs are available in long-acting and short-acting forms. A long-acting patch of methylphenidate (Daytrana) is available that can be worn on the hip.

The pediatric and Adolescents segment will dominate the attention deficit hyperactivity disorder (ADHD)

Estimates suggest that about 4% to 12% of children have ADHD. Boys are 2 to 3 times more likely to have ADHD of the hyperactive or combined type than girls. In the U.S, around 6.1 million children (9.4 percent) between the ages of 2 to 17 are estimated to have been diagnosed with attention deficit hyperactivity disorder (ADHD or ADD).

The American Psychiatric Association (APA) stated that 5 % of children in America have ADHD. But the Centers for Disease Control and Prevention (CDC) put the number at more than double the APAs. According to the CDC, 11 percent of American children, ages 4 to 17, have an attention disorder. Approximate 8.4% of children and 2.5% of adults have ADHD. ADHD is first identified in school-aged children when it leads to disruption in the classroom or problems with schoolwork. ADHD from childhood is a chronic health problem with a significant risk for mortality, the persistence of ADHD, and long-term morbidity in adulthood. Though ADHD has been reported to affect 4.4% of adults, the estimation of the persistence of ADHD from childhood to adulthood has varied widely, ranging from 6% to 66.

Retail Pharmacies segment will dominate the attention deficit hyperactivity disorder (ADHD)

Attention-deficit hyperactivity disorder (ADHD) medications are subject to abuse, misuse, and diversion. Obtaining ADHD prescriptions from multiple prescribers or filled across multiple pharmacies, known as 'doctor shopping,' may reflect such unsanctioned use. No clinical guidelines exist to guide dosing or indications for use, making it difficult to have a standardized treatment approach, especially with differing state regulations. Instead of traditional pharmacies, patients seeking marijuana for medicinal use often go to dispensaries. Some dispensaries focus on stocking and selling only recreational or medicinal products, while others offer both.

Retail Pharmacies would be the safest place for dispensing attention-deficit hyperactivity disorder (ADHD) medications. Pharmacists are experts in medication and play a significant role in dispensing and monitoring medication to ensure safe and optimal use. Dispensing, like other ADHD medications, through a pharmacy is the safest option.

Geographical Analysis

North American region is expected to hold the largest market share in the global attention-deficit hyperactivity disorder market.

A behavioral disorder Attention-deficit hyperactivity disorder (ADHD) affects up to 1 in 20 children in the USA. The predominance of American research into this disorder over the past 40 years has led to the impression that ADHD is largely an American disorder and is much less prevalent elsewhere.

ADHD isn't just a childhood disorder. About 4% of American adults over the age of 18 contend with ADHD behaviors daily. In adulthood, it's diagnosed equally between males and females. During their lifetimes, 13% of men will be diagnosed with ADHD, while just 4.2% of women will be diagnosed. Current prevalence rates of ADHD vary between states, with Nevada having the lowest rate at 4.2% and Kentucky having the highest rate of 14.8%. In addition, due to the launch of products by regional players. For instance, Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., received U.S. regulatory approval in March 2019. Food and Drug Administration (FDA) for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII for the treatment of attention deficit hyperactivity disorder (ADHD) in patients six years of age and older. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the attention-deficit hyperactivity disorder market are Pfizer Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Johnson & Johnson, UCB S.A., Hisamitsu Pharmaceutical Co., Inc., Purdue Pharma L.P. and Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.:

Overview:

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for treating central nervous system (CNS) diseases. Their extensive expertise in product development has been built over the past 30 years. Initially as a standalone development organization, then as a U.S. subsidiary of Shire plc is Supernus Pharmaceuticals Inc. They market products in the United States through their specialty sales force and seek strategic collaborations with other pharmaceutical companies to license products outside the United States.

Product Portfolio:

The company is developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Key Development:

The U.S. Food and Drug Administration (FDA) approved Qelbree, the first new non-stimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents in more than 10 years. Manufactured by Supernus Pharmaceuticals, Inc. Qelbree (viloxazine extended-release capsules) is a selective norepinephrine reuptake inhibitor-a class of drugs often used to treat anxiety and depression, and sometimes ADHD. Qelbree is approved to treat young people with ADHD between the ages of 6 and 17 years.

The global attention-deficit hyperactivity disorder market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Drug Type
  • 3.2. Market Snippet By Age Group
  • 3.3. Market Snippet By Distribution Channel

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing access to health insurance for mental health treatment
      • 4.1.1.2. The rising incidence of ADHD will drive the attention deficit hyperactivity disorder (ADHD) market
    • 4.1.2. Restraints:
      • 4.1.2.1. Side-effects associated with ADHD drugs will hamper the attention deficit hyperactivity disorder (ADHD) market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Drug Type Segment
  • 7.2. Stimulant*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
  • 7.3. Non-stimulant

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Pediatric and Adolescents*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
  • 8.3. Adults

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Retail Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029
  • 9.3. E-Commerce

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2029 and Y-o-Y Growth Analysis (%), 2020-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), ByType
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch
  • 11.5. List of Company with disruptive technology
  • 11.6. List of Start Up Companies

12. Company Profiles

  • 12.1. Supernus Pharmaceuticals, Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Pfizer Inc
  • 12.3. Novartis AG
  • 12.4. Eli Lilly and Company
  • 12.5. GlaxoSmithKline PLC
  • 12.6. Mallinckrodt Pharmaceuticals
  • 12.7. Johnson & Johnson
  • 12.8. Hisamitsu Pharmaceutical Co., Inc.,
  • 12.9. Chongqing Fujin Biology Medical Company
  • 12.10. Wanbang Medical Company LIST NOT EXHAUSTIVE

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us